Mccormick & Co Inc: 1 director

A director at Mccormick & Co Inc sold 1,726 shares at 74.069USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

XVIVO: delivering a solid Q1 2024 performance

XVIVO reported Q1 2024 results with a YoY organic growth of 32% (32% adj. for currency) in net sales raising to SEK 186m. The solid performance was driven by i) thoracic business reporting a 33% YoY growth, totalling SEK 121m sales, with disposables sales rising by 39% as of larger utilization in t

Rec. PTP beat on lower net financials

Melexis : Solid Q1 2024 results and Q2 2024 guidance, implying that th...

>Q1 2024 results in line with expectations on sales but above on profitability - This morning, Melexis reported its Q1 2024 results which were in line with expectations on sales but above on profitability. Revenues came in at € 241.8m, in line with consensus estimates at € 242.3m (vs the guidance range of € 240-245m). They were down 3% q-o-q and up 6% y-o-y. The euro-dollar exchange rate had no impact on sales compared to both the same quarter of last year and the pre...

Forsee Power : Results more negative than expected. The planned end to...

>Result more negative than expected - Yesterday evening, Forsee Power published full-year results that fell short of our expectations. For sales (already published) up 54% y-o-y to € 171m, largely driven by the heavy vehicles segment (85% of 2023 sales), adjusted EBITDA was -€ 6.8m (vs -€ 5.5m est.), albeit showing a y-o-y improvement with the increase in volumes, but also thanks to the stronger capitalisation of R&D costs vs the historical level. Underlying operatin...

Orora Ltd: 1 director

A director at Orora Ltd bought 30,000 shares at 2.130AUD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Sales miss offset by better cost control

Q1 EBITA in line with Infront consensus. Orders up 5% q-o-q gives hope of H2 recovery. We lower '24e EBITA by 1%.

Revaluation of hedge contracts weigh on EBIT

Q1'24 results fast comment

Roche Holding : T1 en ligne - Guidance confirmée, FX moins défavorable...

>T1 sauvé par Vabysmo - Le CA T1 groupe ressort en ligne avec le consensus, en croissance de 2% à tcc (-6% CHF). La pharma (+0.9% vs Css) affiche une croissance de 2% CER (-6% CHF) tirée essentiellement par Vabysmo (96%, 11% vs Css) et Phesgo (+61%, 23% vs Css) dans une moindre mesure. Les produits phares tels que Ocrevus (1.3%, -0.4% vs Css), Hemlibra (0.6%, -3.1% vs Css) ou encore Tecentriq (-6%, -5.5% vs Css) affichent une performance clairement décevante. Le diag...

Melexis : Solid Q1 2024 results and Q2 2024 guidance, implying that th...

>Q1 2024 results in line with expectations on sales but above on profitability - This morning, Melexis reported its Q1 2024 results which were in line with expectations on sales but above on profitability. Revenues came in at € 241.8m, in line with consensus estimates at € 242.3m (vs the guidance range of € 240-245m). They were down 3% q-o-q and up 6% y-o-y. The euro-dollar exchange rate had no impact on sales compared to both the same quarter of last year and the pre...